Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ChemoCentryx stock | 59.55

Own ChemoCentryx stock in just a few minutes.

Posted

Fact checked

ChemoCentryx, Inc is a biotechnology business based in the US. ChemoCentryx shares (CCXI) are listed on the NASDAQ and all prices are listed in US Dollars. ChemoCentryx employs 82 staff and has a trailing 12-month revenue of around USD$76.1 million.

How to buy shares in ChemoCentryx

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for ChemoCentryx. Find the stock by name or ticker symbol: CCXI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ChemoCentryx reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$59.55, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ChemoCentryx, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of ChemoCentryx. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted ChemoCentryx's share price?

Since the stock market crash in March caused by coronavirus, ChemoCentryx's share price has had significant positive movement.

Its last market close was USD$59.55, which is 17.93% up on its pre-crash value of USD$48.87 and 93.85% up on the lowest point reached during the March crash when the shares fell as low as USD$30.72.

If you had bought USD$1,000 worth of ChemoCentryx shares at the start of February 2020, those shares would have been worth USD$836.61 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,326.77.

ChemoCentryx share price

Use our graph to track the performance of CCXI stocks over time.

ChemoCentryx shares at a glance

Information last updated 2020-10-20.
Latest market close USD$59.55
52-week range USD$7.5 - USD$65.43
50-day moving average USD$53.7671
200-day moving average USD$54.6741
Wall St. target price USD$76.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.923

Buy ChemoCentryx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ChemoCentryx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ChemoCentryx price performance over time

Historical closes compared with the close of $59.55 from 2020-11-16

1 week (2020-11-18) 2.90%
1 month (2020-10-23) 1.28%
3 months (2020-08-25) 11.60%
6 months (2020-05-22) -1.19%
1 year (2019-11-25) 638.83%
2 years (2018-11-23) 500.91%
3 years (2017-11-24) 755.60%
5 years (2015-11-25) 704.73%

ChemoCentryx financials

Revenue TTM USD$76.1 million
Gross profit TTM USD$-34,148,000
Return on assets TTM -5.1%
Return on equity TTM -12.1%
Profit margin -39.18%
Book value $6.121
Market capitalisation USD$3.6 billion

TTM: trailing 12 months

Shorting ChemoCentryx shares

There are currently 5.5 million ChemoCentryx shares held short by investors – that's known as ChemoCentryx's "short interest". This figure is 4% up from 5.3 million last month.

There are a few different ways that this level of interest in shorting ChemoCentryx shares can be evaluated.

ChemoCentryx's "short interest ratio" (SIR)

ChemoCentryx's "short interest ratio" (SIR) is the quantity of ChemoCentryx shares currently shorted divided by the average quantity of ChemoCentryx shares traded daily (recently around 681087.68656716). ChemoCentryx's SIR currently stands at 8.04. In other words for every 100,000 ChemoCentryx shares traded daily on the market, roughly 8040 shares are currently held short.

However ChemoCentryx's short interest can also be evaluated against the total number of ChemoCentryx shares, or, against the total number of tradable ChemoCentryx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ChemoCentryx's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 ChemoCentryx shares in existence, roughly 80 shares are currently held short) or 0.118% of the tradable shares (for every 100,000 tradable ChemoCentryx shares, roughly 118 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ChemoCentryx.

Find out more about how you can short ChemoCentryx stock.

ChemoCentryx share dividends

We're not expecting ChemoCentryx to pay a dividend over the next 12 months.

ChemoCentryx share price volatility

Over the last 12 months, ChemoCentryx's shares have ranged in value from as little as $7.5 up to $65.43. A popular way to gauge a stock's volatility is its "beta".

CCXI.US volatility(beta: 1.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ChemoCentryx's is 1.6757. This would suggest that ChemoCentryx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ChemoCentryx overview

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site